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Introduction: Pathologic vertebral fractures are a major clinical concern in the management of cancer patients 
with metastatic spine disease. These fractures are a direct consequence of the effect of bone metastases on the 
anatomy and structure of the vertebral bone. The goals of this study were twofold. First, we evaluated the effect 
of lytic, blastic and mixed (both lytic and blastic) metastases on the bone structure, on its material properties, 
and on the overall vertebral strength. Second, we tested the ability of bone mineral content (BMC) measurements 
and standard FE methodologies to predict the strength of real metastatic vertebral bodies. 
Methods: Fifty-seven vertebral bodies from eleven cadaver spines containing lytic, blastic, and mixed metastatic 
lesions from donors with breast, esophageal, kidney, lung, or prostate cancer were scanned using micro-com-
puted tomography (μCT). Based on radiographic review, twelve vertebrae were selected for nanoindentation 
testing, while the remaining forty-five vertebrae were used for assessing their compressive strength. The μCT 
reconstruction was exploited to measure the vertebral BMC and to establish two finite element models. 
1) a micro finite element (μFE) model derived at an image resolution of 24.5 μm and 2) homogenized FE (hFE) 
model derived at a resolution of 0.98 mm. Statistical analyses were conducted to measure the effect of the bone 
metastases on BV/TV, indentation modulus (Eit), ratio of plastic/total work (WPl/Wtot), and in vitro vertebral 
strength (Fexp). The predictive value of BMC, μFE stiffness, and hFE strength were evaluated against the in vitro 
measurements. 
Results: Blastic vertebral bodies exhibit significantly higher BV/TV compared to the mixed (p = 0.0205) and 
lytic (p = 0.0216) vertebral bodies. No significant differences were found between lytic and mixed vertebrae 
(p = 0.7584). Blastic bone tissue exhibited a 5.8% lower median Eit (p < 0.001) and a 3.3% lower median Wpl/ 
Wtot (p < 0.001) compared to non-involved bone tissue. No significant differences were measured between lytic 
and non-involved bone tissues. Fexp ranged from 1.9 to 13.8 kN, was strongly associated with hFE strength 
(R2=0.78, p < 0.001) and moderately associated with BMC (R2=0.66, p < 0.001) and μFE stiffness (R2=0.66, 
p < 0.001), independently of the lesion type. 
Discussion: Our findings show that tumour-induced osteoblastic metastases lead to slightly, but significantly 
lower bone tissue properties compared to controls, while osteolytic lesions appear to have a negligible impact. 
These effects may be attributed to the lower mineralization and woven nature of bone forming in blastic lesions 
whilst the material properties of bone in osteolytic vertebrae appeared little changed. The moderate association 
between BMC- and FE-based predictions to fracture strength suggest that vertebral strength is affected by the 
changes of bone mass induced by the metastatic lesions, rather than altered tissue properties. In a broader 
context, standard hFE approaches generated from CTs at clinical resolution are robust to the lesion type when 
predicting vertebral strength. These findings open the door for the development of FE-based prediction tools that 
https://doi.org/10.1016/j.bone.2020.115598 
Received 22 February 2020; Received in revised form 5 June 2020; Accepted 12 August 2020    
⁎ Corresponding author. 
E-mail address: philippe.zysset@artorg.unibe.ch (P.K. Zysset). 
URL: https://www.artorg.unibe.ch (P.K. Zysset). 
1 The last two authors share the senior authorship. 
Bone 141 (2020) 115598
Available online 20 August 2020
8756-3282/ © 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/by/4.0/).
T
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
8
7
4
6
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
overcomes the limitations of BMC in accounting for shape and size of the metastatic lesions. Such tools may help 
clinicians to decide whether a patient needs the prophylactic fixation of an impending fracture.   
1. Introduction 
Cancer forms a major cause of morbidity and mortality across the 
world, with an estimated 18.1 million new cases and 9.6 million cancer- 
related deaths in 2018 [1]. Recent improvements in cancer treatment 
have prolonged the lives of many patients, leading to a large number of 
patients being at risk of developing bone metastases at advanced stages 
of the disease [2]. The spine is one of the most frequent site for bone 
metastases [3,4]. Bone metastases are categorized depending on how 
they interfere with the normal bone remodeling. Lytic lesions are 
characterized by the rarefaction of the bone network and the creation of 
lytic foci, while blastic lesions consist in the uncontrolled formation of 
immature and poor quality bone. A mixed metastatic vertebra would 
present both lytic and blastic phenotypes [5,6]. 
Pathological vertebral fractures (PVF), caused when the lesioned 
vertebra can no longer sustain physiological loads [7–10], are an in-
tegral part of spinal adverse events and occur in 15–20% of patients 
with spinal bone metastases [11]. PVF cause pain and immobility [12], 
resulting in severe impairment of quality of life, increased health costs 
[4,13,14], and are directly associated with significant shortening of the 
patient's survival [12,15]. Once fractured, further collapse of the ver-
tebral body may cause loss of vertebral height, kyphoscoliosis and re-
strictive lung disease [16,17]. The most dreaded complication asso-
ciated with PVF is metastatic epidural spinal cord compression, which 
can cause paraplegia or quadriplegia. Systemic therapy and local ra-
diation may halt tumour progression, but they do not restore the 
strength of the diseased vertebra. In fact, radiotherapy is known to 
increase fracture risk [18]. 
The impact of spinal metastasis on the anatomic integrity of the 
vertebral column can be imaged with MRI and CT [17,19–24]. Altered 
geometry, destruction of the pedicles, pain, age, anatomic location, 
lesion type, activity levels, radiographic alignment, previous vertebral 
body collapses and the application of radiotherapy have been identified 
as predictors of fracture risk [25]. Unfortunately, the implications on 
the stability of the spinal column and its risk to undergo catastrophic 
failure have been difficult to quantify with any kind of precision 
[16,26–28]. The Fracture Risk Assessment Tool (FRAX) uses demo-
graphic information such as age, vertebral height, prior fracture, and 
BMD to predict risk of fracture [29]. FRAX demonstrated limited frac-
ture prediction in breast [30] and prostate cancer cohorts [31,32]. The 
Fig. 1. Study overview. Fifty-seven metastatic vertebral bodies (A) were scanned with μCT (B). Based on CT images, metastatic regions were identified (C). 
Nanoindentation measurements (D) were performed on a subset of 12 samples. The remaining 45 samples were compressed to failure in the laboratory with a testing 
setup allowing the free collapse of the vertebral body thanks to a ball joint (E). The image data from the same sample subset was processed to generate micro finite 
element models (F) and, after coarsening to clinical resolution, homogenized finite element models (G). Finally, the micro-mechanical parameters were analysed and 
the in silico results were compared to the experimental data. The colours in (C) correspond to non-involved (gray), lytic (red) and blastic (black) areas. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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spinal instability neoplastic score (SINS) was developed specifically for 
patients with spinal bone metastases [33]. It categorizes PVF risk based 
on vertebral level, pain, lesion, bone quality, radiographic alignment, 
vertebral body collapse and postero-lateral spinal element involvement. 
However, the reproducibility of its imaging components is poor [27]. 
When assessed by members of the Spinal Oncology Study Group, which 
developed SINS, kappa scores for inter-observer agreement were 
(0.244, 0.456, 0.462, and 0.492) for bone quality, alignment, vertebral 
body collapse, and postero-lateral involvement, respectively. Hence, 
although widely used clinically to predict the degree of spinal in-
stability, its prognostic utility for predicting PVF [18,34,35] remains 
controversial [36,37]. It is therefore imperative that clinicians are 
provided with a reliable tool allowing to predict the risk of PVF in 
patients with metastatic spine disease in order to induce the appro-
priate treatment. 
In silico (virtual) tests via finite element (FE) models are increasingly 
used in orthopedic research. Depending on the resolution of the avail-
able CT-images, two distinct FE approaches can be utilised. At high 
resolutions, one approach is to establish a μFE model by first seg-
menting the bone voxels from an image followed by their direct con-
version into hexahedral finite elements. This approach explicitly ac-
counts for the bone micro-structure and is therefore especially 
interesting to simulate the behaviour of pathological bony archi-
tectures. The main drawback of μFE is that such simulations quickly 
lead to models with several millions of degrees of freedom, enforcing 
the use of specialised FE solvers and high-performance computing 
systems. Furthermore, the high-resolution imaging techniques required 
for this type of simulation is currently limited to the peripheral skeleton 
for in vivo applications. Nevertheless, μFE models are considered today's 
gold standard for in silico stiffness estimation [38,39]. A more clinically 
relevant approach is the homogenized finite element (hFE) model, 
where the element size is orders of magnitude larger than the under-
lying micro-structure. Each hFE element implicitly accounts for un-
derlying bone micro-structure by scaling its mechanical properties to 
the surrounding mixture of bone, bone marrow and background 
[40,41]. hFE models have gained substantial interest in clinics, as they 
can be directly generated from clinical CT data, are easily solved on 
standard desktop computers, and were shown to predict fracture risk in 
cohort studies [42,43]. 
FE models provided unique insights into the effect of a range of 
simulated osteolytic defects on the failure strength of cadaver vertebra 
[44–49]. In recent in vivo studies, clinical CT based hFE models were 
even used to evaluate the strength of lytic vertebrae [50,51]. However, 
as encouraging as these studies are, there exists a number of caveats 
before clinical application. For instance, up to 20% of the breast cancer 
patients present blastic or mixed lesions, not just lytic ones [52]. While 
metastases impact the bone architecture, they likely affect its tissue 
properties as well [53,54]. Whether FE models can accurately predict 
the strength of any metastatic vertebrae has yet to be verified. 
This study first investigated the effect of bone metastases (lytic, 
blastic or mixed) on the vertebral structure, the bone tissue properties, 
and on the overall vertebral strength. Second, we tested the ability of 
bone mineral content (BMC) measurements and standard FE meth-
odologies to predict the strength of metastatic vertebral bodies. For this 
purpose, 57 thoracic and lumbar cadaver vertebral bodies obtained 
from 11 donors with prostate, breast, kidney, lung and esophageal 
primary tumours were scanned with μCT, separated in two sub groups 
with 12 samples to be processed for nanoindentation and 45 samples for 
in vitro compression tests. Fig. 1 provides a graphical overview of the 
study. 
2. Materials and methods 
2.1. Sample selection 
Eleven cadaver spines (3 female, 8 male, age 49 y to 71 y, mean 54 
y) were obtained through the Anatomy Gifts Registry (Hanover, MD) 
from donors with known history of solid primary tumours (3 breast, 3 
lung, 2 prostate, 2 kidney, 1 esophageal). Donor demographics are 
presented in Table 1. As part of the exclusion criteria, none of the do-
nors underwent radiotherapy within a 3-month period prior to death. 
Each spine was inserted into a radiolucent imaging chamber filled with 
saline solution followed by degassing for 8 h at 37 ∘C. Using a clinical 
CT scanner (Aquilion 64, Canon Medical System (formerly Toshiba 
Medical), USA), all spines were imaged using standard spine imaging 
protocol (125 kV, 60 ms, ROI: 8.0 in., matrix size: 512, slice thickness: 
500 μm, 396 μm in-plane resolution). Based on the radiological review, 
fifty-seven vertebrae confirmed to present metastatic bone lesions were 
selected for this study. 
2.2. Sample preparation 
The spines were first dissected free of all soft tissues. Each selected 
vertebra was separated from its spine by cutting through the adjacent 
discs, followed by sectioning of the pedicles in the coronal plane to 
remove the posterior elements. Once completed, a diamond coated 
band-saw (Exakt 300, Exakt Technologies, Inc., Germany) was used to 
section both endplates under constant water irrigation. While doing so, 
the transverse plane of the vertebral bodies was defined so that the 
maximal vertebral section height could be generated. This process re-
sulted in plano-parallel vertebral body sections ranging from 12 mm to 
25 mm in height. To assess the parallelism of the surfaces, the speci-
men's height was measured at four locations (anterior, posterior, left 
and right) using a mechanical calliper (Mitutoyo 530 (150 mm, 
0.01 mm accuracy), Japan). Samples with a difference in height larger 
than 0.1 mm were polished (LaboPol-20, Struers, Denmark) until inter- 
measurement differences were less than 0.1 mm. 
2.3. Micro CT and metastases classification 
Each vertebral section was scanned with μCT (μCT100, Scanco 
Medical, Switzerland) at 24.5 μm isotropic voxel size (tube voltage: 
70 kV, tube current: 200 μA, integration time: 500 ms). High-frequency 
noise contained in the images was reduced with a Gauss filter (Sigma: 
0.8, Support: 1) [55,56] and a custom script (IPL, Scanco Medical, 
Switzerland) was used to generate a mask separating each vertebra 
from its background. For each image, the BMC within that mask was 
computed. 
The optimal bone segmentation threshold for each μCT image was 
computed based on an adaptive threshold algorithm [57,58]. The 
computed segmentation thresholds of all individual measurements were 
averaged and the mean value (429 ± 56 mgHA/cm3) was selected to 
segment all samples. The resulting segmented μCT images were used for 
the computation of the overall (i.e. cortical + trabecular regions) bone 
volume fraction (BV/TV) of the samples and for generating the μFE 
models. 
Table 1 
Donor demographics summarising primary tumour, age, race (black/cauca-
sian), sex, height and weight.         
Spine ID Primary Age Race Sex Height [cm] Weight [kg]  
A Prostate  55 C M  183  68 
B Prostate  71 C M  188  68 
C Lung  53 C M  175  86 
D Breast  59 C F  170  79 
E Lung  60 B M  183  82 
F Lung  49 B M  178  68 
G Esophageal  52 C M  170  127 
H Breast  60 C F  165  68 
I Kidney  71 C M  170  54 
J Kidney  56 C M  180  79 
K Breast  60 C F  163  41 
M.A. Stadelmann, et al.   Bone 141 (2020) 115598
3
Finally, the μCT images were reviewed by three clinicians, an or-
thopedic surgeon and two radiologists, for the radiographic appearance 
of the bone. Using a consensus table, each sample was graded as either 
lytic, blastic or mixed. For each sample, the lesions were only outlined 
as the definition of the boundaries is delicate. Pixel-wise segmentation 
of the lesions would not have been possible with a regular thresholding 
procedure because the gray-value of the metastatic tissue is similar to 
non-involved bone. A large manual effort or advanced machine learning 
techniques - prone to errors given the small, heterogeneous data-set - 
would have been required. As a consequence, the exact metastatic vo-
lumes were not measured. 
2.4. Nanoindentations of the metastatic and non-involved bone tissues 
Twelve samples, randomly selected to undergo nanoindentation 
measurements, were further processed using a diamond coated band- 
saw to obtain 3 mm thick parallel sections (Exakt 300, EXAKT 
Technologies, Inc., Germany). Following the procedure described in 
[59], the sections were infiltrated with methylmethacrylate (MMA). 
Each embedded section was cut to fit the nanoindenter sample holder 
and a micro-milling system (Polycut ultra-miller, Reichert-Jung, Ger-
many) was used to ensure the specimen's parallel surface with respect 
to the specimen holder. To remove scratches caused by the micro-mil-
ling process, the surface was polished (LabPol-5, Streuers, Denmark) 
with a silicon carbide paper (P4000, Struers, Denmark), finished with a 
1 μm diamond paste [60], cleaned in an ultrasonic bath (Type 88,169, 
Bioblock Scientific AG, Switzerland) for five minutes to ensure that no 
residue particles remained on the surface and dried at room tempera-
ture for 24 h before measurement. 
An Ultra Nanoindentation Tester (CSM instruments, Switzerland) 
was used to perform indentation measurements (Berkovic tip geometry, 
depth: 1 μm, loading speed: 100 mN/min, unloading speed: 400 mN/ 
min, holding time: 30 s) [61]. Following the findings by Wolfram et al. 
[62], thirty-two indentation points were defined on bone trabecule 
located within each region (lytic, blastic or non-involved), resulting in 
787 indentation measurements in total. Within each selected region, 
eight distinct trabeculae were identified, with four measurements per-
formed in the transverse and four measurements in the axial direction 
of the trabecula. For both directions, two measurements were per-
formed in the inner region of the trabecula and two in the outer region. 
For highly blastic regions, these locations could not appropriately be 
defined, and thus the indentations were evenly spread out over the 
entire blastic region. For some highly lytic regions, the trabeculae were 
completely resorbed (e.g. Fig. 3 (A)). In these cases, the nanoindenta-
tions were performed in the bone trabeculae surrounding the bone 
cavity. For each measurement, the indentation modulus (Eit), the elastic 
(Wel), the plastic (Wpl) and the total indentation work (Wtot) were 
computed. The fraction Wpl/Wtot can be interpreted as a measure of 
ductility, low values (towards 0) suggesting a brittle and high values 
(towards 1) suggesting a ductile material. 
2.5. Mechanical testing 
Prior to mechanical testing, the vertebral levels allocated for me-
chanical testing (n = 45) were equilibrated in 0.9% NaCl saline solu-
tion for one hour at room temperature. Based on the protocol described 
by Dall'Ara et al. [63], a fracture was induced by compressing the 
vertebral body between two steel plates mounted on a servo-hydraulic 
compression system (858 Mini Bionix II, MTS, Eden Prairie, USA). Both 
steel plates had their contact surfaces sandblasted to prevent the sample 
from sliding during the compression test. The caudal plate was rigidly 
fixed to the construct. The cranial plate was mounted to the loading 
mechanism via a ball joint. 
To induce an anterior wedge-shaped fracture, the specimen's center 
of mass was computed from the μCT images and digitally shifted 
anteriorly by a distance equal to 10% of the antero-posterior width of 
the bottom surface. The resulting position and outer contour of the 
bottom surface were printed on a sheet of paper and placed on the 
testing system to allow for the precise positioning of the sample (Fig. 1 
E) [63]. The cranial load plate was lowered until a tare load of 25 N was 
recorded to confirm the contact. A uniaxial displacement was applied at 
a rate of 5 mm/min [40,55] until failure was registered or the max-
imum force (15 kN) of the MTS built-in load cell (model: 662.20D-04) 
was reached. The outcome of the testing procedure was the vertebral 
strength (Fexp), defined as the maximum measured compressive force. 
Seven samples were excluded from the statistical analysis as they 
could not be fractured because their strength exceeded the limit of the 
load cell. 
2.6. Generation of the linear μFE models 
The bone voxels of the segmented μCT images (Section 2.3) were, 
after removal of non-connected structures, converted into linear eight- 
node hexahedral finite elements, yielding on average 316 million ele-
ments per sample. Young's modulus was set to 10 GPa and Poisson's 
ratio to 0.3 [62]. 
The nodes of the caudal surface were set as fully constrained. To 
limit the degrees of freedom of the model, the nodes of the cranial 
surface were set to allow motion only along the loading direction. The 
μFE models were solved for stiffness (KμFE) using Parosol [64,65] on a 
Linux based cluster (16 Intel Xeon E5 cores, 256 GB RAM), resulting in 
a mean computation time of six hours per sample. The outcome of the 
μFE models was the in silico sample stiffness (KμFE). 
Four samples were excluded from the statistical analysis as they 
could not be processed due to RAM limitations on our system. 
2.7. Generation of the non-linear homogenized FE models 
The hFE model generation is based on a method first described by 
Chevalier et al. [55]. Pahr et al. [66] validated this modelling approach 
for vertebral bodies with various degrees of osteoporosis using the 
testing protocol defined by Dall'Ara et al. [63]. 
First, all negative BMD values in the masked μCT images (Section 
2.3) were clipped to zero to prevent negative local BMD values caused 
by air bubbles. The corrected BMD images were down-sampled to 
0.98 mm isotropic voxel size to mimic the resolution of clinical CT 
images. This voxel size was chosen as it represents a worst-case clinical 
CT resolution, it shortens the computation times for potential clinical 
applications and is similar to the 1 mm element size employed by the 
only FDA-approved clinical use for FEA modelling of vertebral strength 
(VirtuOst, O.N.Diagnostics Inc., USA, http://ondiagnostics.com). The 
resulting voxels were converted into eight-node hexahedral finite ele-
ments. Each element was assigned a local BV/TV, computed by dividing 
the element BMD with the mean tissue BMD of the entire volume 
(BMD_tissue = 684 mgHA/cm3). Each voxel was then assigned a fixed 
transverse isotropy with the main direction along the cranio-caudal axis 
of the vertebra (fabric eigenvalues: 1.249, 0.894, 0.894) [55]. 
The constitutive law and material constants were taken from Pahr 
et al. [66]. In brief, an anisotropic, time-dependent, BV/TV-based 
constitutive law was implemented as an Abaqus (V.6.13, Dassault 
Systems, France) user material (UMAT). The law includes linear elas-
ticity, yielding and plasticity with the accumulation of damage and 
irreversible strains. 
To replicate the experimental boundary conditions, the nodes of the 
caudal surface were constrained in all directions. The nodes of the 
cranial surface were kinematically coupled to a virtual ball joint. 
Loading conditions were prescribed with a uniform axial displacement 
at a rate of 5 mm/min applied to the ball joint. The models were solved 
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using six 3.2 GHz cores and lasted approximately thirty minutes per 
simulation. The outcome of the hFE models was a predicted value of the 
in silico sample strength (FhFE). 
2.8. Statistical analysis 
All statistical analyses were performed in JMP pro (14, SAS, NC). All 
reported p values are two-tailed with an alpha level set to 0.05. 
Univariate statistics were used to summarise the specimen's demo-
graphics, bone properties, indentation properties, measured vertebral 
strength, and FE predicted vertebral strength. Descriptive statistics 
were used to test whether 1) the overall BV/TV values, 2) indention 
parameters (Eit and Wpl/Wtot), and 3) the measured vertebral strength 
(Fexp), were non-normally distributed. 
The sampling of multiple vertebrae per spine for mechanical testing 
(45 vertebrae from 11 spines) and the selection of multiple indentation 
sites for each of the additional twelve vertebrae, can introduce none- 
independence (clustering) of the data. For example, strength values for 
vertebrae obtained from the same spine could be correlated due to 
anatomical and genetic factors. Linear mixed model (LMM) analysis 
[67] was used to test for the effect of multiple indentation sites, with 
lesion type entered as a fixed variable, Eit or Wpl/Wtot entered as the 
outcome variables, and Spine ID (indicating the spine from which the 
vertebral levels were obtained (Table 1)), set as a random variable. 
LMM analysis was similarly applied to test for the effect of selecting 
multiple vertebrae per spine on the association between 1) BMC, 2) 
KμFE, and 3) FhFE, entered as fixed effects, with Spine ID entered as a 
random variable. The measured strength (Fexp), entered as the outcome 
variable. 
Based on the findings of the LMM analysis, Kruskal–Wallis one-way 
ANOVA was used to test for the effect of bone lesion classification on 
differences in the indentation parameters, Eit and Wpl/Wtot. Steel- 
Dwass analysis was used for posthoc comparisons within each grouping. 
We applied regression analysis to test for the association of 1) BMC, 2) 
KμFE, 3) FhFE, with the measured strength (Fexp). 
3. Results 
3.1. Influence of the metastases on the bone structure 
Fig. 2 presents axial μCT slices and photographs of typical lytic, 
mixed, and blastic vertebrae. Additionally, μCT mid-planes and planar 
projections of all samples are provided as supplementary material. 
Vertebrae classified as osteolytic generally presented a thinning of the 
cortex and rarefaction of the trabeculae through the entire vertebra, but 
focal bone loss (cavities) was also found (Fig. 3 A). Vertebrae classified 
as blastic were characterized by an overall increased bone density 
(Figs. 2C, 3C). Local scleroses could also be observed in vertebrae 
classified as mixed (Fig. 2B). Finally, mineralized tissue was sometimes 
found in the inter-trabecular space (Fig. 3 B). 
Descriptive statistics revealed BV/TV to be non-normally distributed 
(Shapiro-Wilk W test, Osteoblastic: p = 0.0036, Mixed: p = 0.0404, 
Osteolytic: p = 0.0201). Lesion classification significantly affected the 
BV/TV values between the lesion groups (Kruskal-Wallis test: χ2 = 
12.08, p = 0.0024). Post-test analysis (Steel-Dwass all-pairs test) re-
vealed vertebrae with osteoblastic lesions to exhibit significantly higher 
BV/TV values compared to vertebrae with mixed (p = 0.0205) and 
osteolytic (p = 0.0216) lesions. No such statistically significant differ-
ences were found between the osteolytic and mixed lesions vertebrae 
(p = 0.7584). 
3.2. Influence of the metastases on the bone tissue properties 
A total of 787 indentation points were measured with 328 mea-
surements performed in trabecular bone regions with no radiological 
evidence of metastatic involvement, 366 measurements in osteoblastic 
regions, and 93 measurements in osteolytic regions. Table 3 sum-
marizes the type of lesion measured on each sample. 
Fig. 4 presents a graphical summary of the distribution of the in-
dentation modulus (Eit) and the ratio of plastic to total work (Wpl/Wtot). 
Eit and Wpl/Wtot were found to be non-normally distributed (Shapiro- 
Wilk W test, p < 0.001 respectively), yielding a median (Q1-Q3) of 
Fig. 2. A pictorial illustration of μCT axial images of vertebral bodies containing (A) osteolytic (lung primary, F 250), (B) mixed (breast primary, D 168) and (C) 
osteoblastic (breast primary, H 217) metastases. The row below provides photograph of the corresponding vertebral bodies. 
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14.30 (12.42–16.43) GPa for Eit and 0.79 (0.77–0.82) for Wpl/Wtot. 
LMM analysis revealed Spine ID to have no significant effect on the 
association between bone lesion type and either Eit (Wald p = 0.063) or 
Wpl/Wtot (Wald p = 0.058). Kruskal-Wallis test revealed a statistically 
significant difference between the lesion groups for Eit (χ2 = 35.28, 
p < 0.001) and for Wpl/Wtot (χ2 = 58.25, p < 0.001). Post-hoc analysis 
(Steel-Dwass all-pairs test) demonstrated that, compared to non-in-
volved and osteolytic bone tissues, osteoblastic bone tissue exhibited a 
5.8% lower median Eit value (P < 0.001) and a 3.3% lower median 
Wpl/Wtot value (P < 0.001). We found no statistically significant dif-
ferences for either Eit or Wpl/Wtot between non-involved bone tissue 
and bone tissue surrounding osteolytic lesions (p = 0.441 and 
p = 0.7998, respectively). 
3.3. Influence of the metastases on the experimental vertebral strength 
Fig. 5 presents typical loading curves and the mechanical integrity 
of the samples based on the lesion group. The corresponding numerical 
values are summarized in Table 4. 
Fexp was found to be non-normally distributed (Shapiro-Wilk W test 
p = 0.028) with a median (Q1-Q3) strength value of 5.82 (3.03–6.02) 
kN for the osteolytic vertebrae, 5.91 (4.72–8.08) kN for the mixed le-
sions vertebrae and 10.83 (5.85–14.00) kN for osteoblastic vertebrae. 
Kruskal-Wallis test revealed a statistically significant difference in 
Fexp between the lesion groups (χ2 = 9.8, p = 0.0074). Post-test ana-
lysis (Steel-Dwass all-pairs test) showed vertebrae with osteoblastic 
lesions to exhibit higher median Fexp compared to vertebrae containing 
mixed (86.1%, p = 0.0250) and osteolytic (86.1%, p = 0.0115) lesions. 
We did not find such significant differences between vertebrae with 
mixed and osteolytic bone lesions. 
3.4. Can BMC and FEA accurately predict vertebral strength despite the 
metastases? 
Fig. 6 illustrates the association of Fexp with the specimen's (a) BMC, 
(b) KμFE, and (c) FhFE. LMM analysis revealed spine ID to have no sig-
nificant effect on the strength of the association between BMC 
(p = 0.090), KμFE (p = 0.225) and FhFE (p = 0.161). 
Fig. 3. Close-up on the observed alterations. (A) Osteolytic lesions sometimes lead to lytic foci (lung primary, C 209), (B) “islands” of mineralized tissue were often 
seen in the bone marrow of vertebrae with blastic metastases (prostate primary, B 280), (C) blastic lesions resulted in a very dense trabecular network (prostate 
primary, A 180). 
Fig. 4. Nanoindentation results per lesion type. For both indentation modulus (Eit) and ratio of total to plastic work (Wpl/Wtot), the blastic bone showed significantly 
lower values compared of non-involved bone. No such statistical differences were found for similar comparison with osteolytic bone. 
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Ordinary least regression analysis established that BMC values were 
moderately associated with Fexp (F(1, 36) = 131.33, p < 0.001) with 
the variation in BMC explaining 66% of the variation in Fexp (Fig. 6 (a)). 
μFE predicted stiffness (KμFE) values were moderately associated with 
Fexp ((F(1, 36) = 70.174, p < 0.001) with the variation in KμFE ex-
plaining 66% of the variation in Fexp (Fig. 6 (b)). By comparison, hFE 
predicted strength (FhFE) values were strongly associated with Fexp (F(1, 
36) = 131.32, p < 0.001) with the variation in FhFE explaining 78% of 
the variation in Fexp (Fig. 6 (c)). 
The linear regressions established between Fexp and BMC, KμFE, and 
FhFE for each lesion group is presented Table 2. These numbers tend to 
confirm the robustness of the hFE approach in predicting Fexp. Re-
gression analysis for BMC and μFE models showed lesion phenotype 
specific differences in the model's prediction strength (Table 4), with 
both variables showing a weak association for osteolytic vertebrae. 
Interpretation of the models for the osteolytic and mixed lesion phe-
notype however has to be done with care due to the relatively low 
number of specimens in both groups as compared to the osteoblastic 
group. 
4. Discussion 
The first aim of this study was to employ μCT, nanoindentations, 
and compression tests to evaluate the impact of tumour-induced bone 
metastases on the structure, tissue-level, and organ-level mechanical 
properties of human vertebral bone obtained from donors with solid 
tumours. The second aim was to evaluate the ability of BMC and CT- 
based FE models, generated at high and clinical resolutions, to predict 
the measured compressive strength of pathologic cadaver vertebrae 
containing osteolytic, osteoblastic and mixed bone lesions. 
4.1. Effect of the metastases on the bone structure and tissue 
Osteolytic vertebrae (lung, kidney, or breast cancer) exhibited the 
lowest BV/TV of the three lesion groups, indicative of the lesion- 
mediated rarefaction of the vertebral bone network. As reported in the 
literature, infiltration of vertebral bone with osteolytic bone metastasis 
resulted in the degradation of the trabecular bone microarchitecture, 
the creation of osteolytic foci within this network, and destruction of a 
significant portion of the cortex Hojjat and Whyne [68]; Nazarian et al. 
[53]; Tamada et al. [54]. 
At the tissue level, osteolytic metastases were reported to affect the 
organisation of collagen fibers [69–71], mineral phase and crystal size 
[70,72], and to degrade collagen cross-linkage [73] in a murine model, 
without impacting the indentation modulus and hardness compared to 
healthy bone [69,73]. These results are surprising because such al-
terations would be expected to affect bone tissue material properties. 
Yet, using human samples, we found no significant difference between 
lytic and non-involved tissue in terms of Eit and Wpl/Wtot ratio. These 
findings suggest that the reduced strength of osteolytic vertebrae is 
predominantly due to the rarefaction of the bone architecture (lower 
BV/TV) rather than changes in the tissue properties. 
Osteoblastic vertebrae (breast, kidney, lung, esophageal, or prostate 
cancer) exhibited higher median BV/TV values, (+53%) compared to 
vertebrae with mixed or osteolytic lesions. Trabeculae in these samples 
appeared abnormally thick and interconnected, sometimes without 
clear preferred orientation. This visual impression is confirmed by 
previous μCT studies [53,54] reporting high BV/TV values (20–50%) 
with a significantly higher number of bone trabeculae, trabecular sur-
face, but a lower degree of structural anisotropy [54], when compared 
to healthy bone. Remarkably, several of the osteoblastic vertebrae in 
our study showed sub-regions with up to 90% BV/TV, indicating an 
almost compact bone. 
Despite an increase in bone volume and osteoid deposition [54], 
blastic bone is of inferior quality: we measured a 5.8% lower Eit and a 
3.3% lower Wpl/Wtot compared to lytic and non-involved bone. Other 
authors reported a 19.2% lower indentation modulus and 17.9% lower 
hardness in a murine model [70]. The lower intrinsic properties can be 
explained the high amount of new, less mineralized tissue and un-
organised, woven collagen structure [74,75] likely induced by tumour- 
derived growth factors [76] rather than mechanical stimuli. Assuming 
constant yield strains across BV/TV, a decrease in tissue elastic modulus 
(−5.8%) would lead to a similar reduction in yield stress. Yet, blastic 
vertebrae were significantly stronger the lytic and mixed ones (up to 
+700% in strength). These findings suggest that the increased strength 
of osteoblastic vertebrae is predominantly due to the densification of 
the bone architecture (higher BV/TV) despite lower tissue properties. 
Based on these results, the difference in tissue properties plays a 
minor role on vertebral strength compared to bone mass. We thus chose 
to employ a standard BV/TV-driven constitutive law and material 
constants obtained from healthy bone tissue for the finite element si-
mulations in this study. 
Fig. 5. (A) Typical experimental load-displacement curves for lytic, mixed, and blastic vertebral bodies, the number in the legend identifies the samples (Table 4). (B) 
Vertebral bodies containing osteoblastic metastases showed significantly higher Fexp than those containing mixed or osteolytic lesions. 
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4.2. Effect of the metastases on the in vitro strength 
The osteoblastic vertebrae demonstrated markedly higher strength 
and BMC values compared to vertebrae with mixed (a median increase 
of 36.7% and 26.9% respectively) and osteolytic (a median increase of 
34.5% and 137.5% respectively) lesions. Independent of the lesion 
phenotype, BMC values were moderately associated with Fexp (R2 = 
0.65), which is in close agreement with correlations obtained with 
none-pathologic human vertebrae [77]. Interestingly, vertebrae with 
mixed lesions showed little difference in strength compared to lytic 
samples (+2% median), despite a markedly higher BMC (+87.1% 
median). These findings may 1) help explaining the difficulties in as-
sessing the effect of mixed lesions on the vertebral strength based on the 
radiological appearance alone and 2) suggest that the strength of mixed 
vertebrae is predominantly determined by the location of the osteolytic 
lesions. 
Previous studies have evaluated the effect of tumour size, shape and 
location based on non-pathologic vertebrae with artificial, continuous 
defects [46–48,78–81]. An artificial cavity cannot not mimic an array of 
smaller, diffused lytic lesions, or a blastic metastasis. To the best of our 
knowledge, our study is the first one to quantify the effect of real bone 
metastases on the strength of human vertebral bodies. 
4.3. Predictions of in vitro strength 
Homogenized FE models were shown to predict vertebral strength 
better than purely densitometric measures such as BMC, in part by 
accounting for the 3D distribution of bone mass [60]. Our findings go 
one step further and demonstrate that homogenized FE modelling can 
reliably predict the strength of the pathologic vertebrae, without having 
to adapt the material model to the type of metastasis. In a previous 
work, Pahr et al. [66] validated the modelling approach against normal 
Fig. 6. Linear relationships established between the in vitro strength (Fexp) and (A) bone mineral content (BMC), (B) μFE stiffness (KμFE), and (C) hFE strength (FhFE). 
The black line represents the linear regression through all data points specified by the equation given within the individual plots. The gray band around the regression 
lines represent the 95% confidence interval. Additionally in (B), the green line represents the linear regression reported by [66] for cancer-free vertebrae. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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to osteoporotic vertebral bodies. Interestingly, both the slope and the 
intercept of their linear regression are within the 95% confidence in-
terval of our values, with a similar coefficient of determination (R2 = 
0.77 [66] vs. R2 = 0.78). These findings reaffirm the importance of 
incorporating the spatial contribution of the bone architecture for 
predicting the strength of bone, pathological or not. 
Surprisingly, however, the μFE simulation, which explicitly ac-
counts for the bone architecture, yielded only a moderate association 
between KμFE and Fexp (R2= 0.65). Contrary to FhFE, KμFE was less 
strongly related to the strength of the lytic vertebrae compared to that 
of the blastic or mixed ones (Table 2). We posit that a reason for such 
difference is the uniaxial loading condition. Contrary to the hFE model, 
we were not able to replicate the ball joint of the experimental setup 
because of the high number of degrees of freedom involved in the μFE 
simulation. As stiffness is measured for very small displacements, a 
major impact was not expected. An additional source of discrepancy is 
the sensitivity to the segmentation threshold. Set slightly too high, it 
can disconnect thin trabeculae in the μFE model and artificially lower 
KμFE. Larger vertebrae would also appear thinner, but are less likely to 
disconnect. Similarly, a threshold set too low would close the tight 
trabecular gaps of the blastic metastases. Finally, a more mechanistic 
explanation is that lytic lesions affect the strain distribution within 
trabeculae causing significant variation in local mechanics and early 
initiation of buckling in the experiments [68,82]. 
In several of the osteoblastic vertebrae, we observed calcified 
structures within the marrow spaces (e.g. Fig. 3 B). Although we per-
formed no histological examination, these structures may originate 
from osteoid depositions or cartilage mineralization, likely the result of 
the lesion mediated disruption of the normal skeletal homeostasis. At 
the given μCT resolution, most of them seem disconnected from the 
main trabecular architecture - indicating that they do not contribute to 
bone stability - and were thus removed from the μFE models. Although 
such depositions cannot be distinguished on clinical CT (or down-scaled 
μCTs in our case), they contribute to the measured mineral content. 
Given these structures' unclear contribution to bone strength, the 
standard interpretation that increased mineral content leads to stronger 
bone must be made with care in the context of bone metastases. Still, 
the hFE approach was robust enough to yield equivalent strength pre-
dictions as for cancer-free vertebral bodies Pahr et al. [66]. 
Previously, studies using FE models for predicting vertebral strength 
in vivo based on clinical CT images of cancer patients [50,51] assumed 
that finite elements models validated on healthy vertebrae would be 
able to predict the strength of metastatic vertebrae as well. To the best 
of our knowledge, this is the first study to actually validate the FE 
models on real metastatic vertebral bodies, despite alterations of bone 
mass, structure, and tissue properties. 
4.4. Justification for the testing protocol 
Studies on the effect of the intervertebral disc on the structural re-
sponse of spines have yielded conflicting results. In non-pathologic 
spines, the state of the intervertebral disc was reported to affect the 
strength of the vertebral body [83–85], as well as its failure pattern 
[86,87]. In spine segments with mechanically simulated large single 
osteolytic defect, Whyne et al. [88] reported disc degenerative state to 
have little effect on vertebral bulging under compression. By contrast, 
Alkalay and Harrigan [44] showed that the deformation pattern within 
the endplate and disc was affected by the lytic defect. Given these 
conflicting reports and the need to guarantee controlled loading and 
boundary conditions for testing and consequent modelling Dall'Ara 
et al. [63], we decided to remove the intervertebral discs to better 
isolate the lesion's impact on the vertebral strength. 
This decision leaves only two testing options: endplate embedding 
in a rigid resin [55] or endplate removal [63]. Using CT-based hFE 
models, we have previously demonstrated that 1) the two techniques 
result in the same strength [89] and 2) models with embedded end-
plates provide good prediction of the strength of vertebrae loaded ex-
perimentally via their intervertebral discs [90]. Removing the endplates 
and intervertebral discs allows us to capture strength variation, without 
having to deal with the disc or embedding material. Finally, although 
there is a clinical agreement regarding the importance of the posterior 
elements in the stability and risk of fracture of pathologic spines [91], 
the effect of lesion phenotype on the structural integrity of the posterior 
elements remains unstudied. Thus it is unclear how the stability of the 
spine segment would be affected. Given the lack of information, we 
decided to section the pedicles and focus the study on the vertebral 
body. Although our test configuration does not fully capture the 
structural response of the vertebrae in the context of a spine unit, it is 
fully justified, given the aims of the study. 
Numerous studies have performed in vitro testing of vertebrae with 
artificial defects using more elaborated setups [46–48,78–81]. How-
ever, the diverse experimental setups (e.g. high loading rates versus 
quasi-static loading) make a direct comparison to these studies difficult. 
Choosing a well-controlled and proven testing protocol allowed, despite 
its limitations, a comparison with similar experiments performed on 
cancer-free samples Dall'Ara et al. [63]; Pahr et al. [66]. 
4.5. Justification for generating the hFE models from μCT 
In order to identify and select levels with bone metastases, we did 
image the full spines using clinical CT ex vivo. The FE models, however, 
were derived from the μCT scans of the vertebral bodies. While the μFE 
models require the high-resolution CTs, hFE models could have been 
generated from clinical CTs. However, the clinical CT images were 
performed on the intact vertebral columns, and were acquired without 
calibration phantom rendering a conversion of native Hounsfield units 
into to BMD values impossible without additional assumptions. On the 
other hand, the μCT acquisitions were calibrated and performed on 
vertebral sections prepared for the experiments (intervertebral discs 
and endplates removed). To compare experimental and μFE values to 
clinical CT based hFE predictions, we would have had to downscale and 
register the μCT images to find the correct vertebral section in the 
clinical CT, which would have been prone to errors. Finally, average 
densitometric variables such as BMD correlate highly between μCT and 
clinical CT [92]. In summary, using the coarsened μCT to generate the 
hFE model allowed for a direct, simple, and reproducible model gen-
eration and BMD evaluation. 
Table 2 
Results of the linear regressions between vertebral strength (Fexp), bone mineral 
content (BMC), μFE stiffness (KμFE), and hFE strength (FhFE) for all, lytic, blastic, 
and mixed samples. Based on these numbers, hFE models seem to predict 
vertebral strength better than the other methods and is more robust to the type 
of lesion.      
Regression equation R2  
Relationship between Fexp [kN] and BMC [mgHA] 
All samples Fexp = 0.002 ⋅ BMC + 1.251 0.65 
Lytic Fexp = 0.010 ⋅ BMC + 2.848 0.32 
Blastic Fexp = 0.002 ⋅ BMC + 0.483 0.57 
Mixed Fexp = 0.002 ⋅ BMC + 0.412 0.77  
Relationship between Fexp [kN] and KμFE [kN/mm] 
All samples Fexp = 0.084 ⋅ KμFE + 2.945 0.65 
Lytic Fexp = 0.047 ⋅ KμFE + 2.912 0.33 
Blastic Fexp = 0.098 ⋅ KμFE + 2.424 0.88 
Mixed Fexp = 0.065 ⋅ KμFE + 4.105 0.51  
Relationship between Fexp [kN] and FhFE [kN] 
All samples Fexp = 0.781 ⋅ FhFE + 0.937 0.78 
Lytic Fexp = 1.310 ⋅ FhFE - 1.896 0.76 
Blastic Fexp = 0.755 ⋅ FhFE + 0.971 0.64 
Mixed Fexp = 0.818 ⋅ FhFE + 1.082 0.90 
M.A. Stadelmann, et al.   Bone 141 (2020) 115598
9
4.6. Limitations 
Our study has several limitations, other than those associated with 
the in vitro testing of cadaver spines. Although we had access to the 
donor's medical history, including identification of primary cancer, 
surgical, chemotherapy, and medication, we received little information 
regarding radiotherapy treatments and, if so, what levels were treated. 
Radiotherapy, highly prevalent in this patient population, is increas-
ingly recognised as a risk factor for PVF [18,93,94]. In a study of 
gamma-irradiated (31 kGy) human cancellous allograft bone, [95] re-
ported a reduction of up to 66% in bone strength while no significant 
effects were observed for the stiffness of the bone. Although the ra-
diation dose absorbed by a patient during radiotherapy is lower by 
more than two orders of magnitude than the one employed by 
Schwiedrzik et al., we cannot rule out that some of the outliers in the 
present dataset may have been caused by previous radiotherapy treat-
ments. 
With the study sample classified predominately as osteoblastic, we 
had limited number of vertebrae classified as osteolytic or with mixed 
lesions. Combined with the large variation in strength values for each 
group, we had a reduced statistical power for comparisons between the 
lesion phenotypes. We still provided the correlations per group for in-
formation, but more samples are needed in each group before drawing 
conclusions. 
Finally, we did not present experimental values for vertebral stiff-
ness. The reason for this omission was that we were not able to produce 
perfectly parallel sections during sample preparation, which would 
have affected the stiffness measurements. However, since the clinical 
interest is to estimate fracture risk, strength seems to be the essential 
variable to focus on. Therefore, and to avoid misinterpretations, we 
decided to exclude the experimental stiffness from the evaluation. 
4.7. Conclusions 
In conclusion, this novel study shows that indentation properties of 
osteoblastic bone are slightly lower compared to osteolytic or normal 
regions. Although experimental confirmation, for instance by Raman 
spectroscopy, will become necessary, this small reduction may be at-
tributed to the lower mineralization and woven nature of the new bone 
formed in blastic regions. However, this difference in tissue properties 
plays a secondary role on vertebral strength compared to bone mass. As 
a consequence, standard homogenized FEA successfully predicts the 
strength of vertebral bodies without having to adapt the material model 
to the metastases. Compared to BMC, FEA accounts for the position, 
shape and size of lytic or blastic lesions and delivers improved strength 
prediction. Given that FEA can detect individuals at risk of fracture in a 
clinical setup [96], the hope is to develop a similar tool to help the 
clinicians decide whether a metastatic patient is at risk of fracture and 
needs prophylactic surgery [97]. 
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Appendix A 
Table3 
Lesion type measured by nanoindentation. The column ID combines the spine ID and the sample ID. Marks between parentheses were not measured 
due to absence of trabecular structure at the given location.       
ID Level non-in-
volved 
blastic lytic  
A 190 L3  ✓ ✓ 
B 279 L3 ✓ ✓  
B 276 L2 ✓ ✓ (✓) 
C 209 T7 ✓  ✓ 
D 176 T12 ✓ ✓  
E 289 T11 ✓ ✓  
F 249 L1 ✓ ✓  
G 187 T7 ✓ ✓  
H 230 T10  ✓  
I 221 T10   ✓ 
J 301 T11 ✓ ✓ (✓) 
K 242 L2  ✓   
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Table 4 
Overview of the investigated vertebral bodies: ID combines the spine ID and the sample ID where the spine ID specifies the origin vertebral column (Table 1), 
vertebral level, metastatic lesion type, bone volume ratio (BV/TV), experimental strength (Fexp), μFE stiffness (KμFE), bone mineral content (BMC) and hFE strength 
(FhFE). Missing entries represent samples that did not fail during experimental testing or μFE simulations that could not be solved due to insufficient RAM on our 
system (256 GB).          
ID Level Type BV/TV Fexp [kN] KμFE [kN/mm] BMC [mgHa] FhFE [kN]  
A 180 L1 Blastic  0.36  –  –  13,072.43  27.93 
A 181 T9 Blastic  0.41  –  –  6664.84  21.63 
A 183 T10 Blastic  0.44  –  –  7709.67  22.66 
A 185 L4 Blastic  0.47  –  –  15,242.64  45.51 
B 280 T11 Blastic  0.23  8.48  59.78  5671.98  13.17 
B 283 T12 Blastic  0.14  7.08  36.36  3943.31  7.09 
B 284 T7 Blastic  0.14  4.33  26.02  2290.62  4.63 
B 286 T10 Blastic  0.16  5.59  40.03  3224.38  6.18 
C 201 L2 Blastic  0.19  8.21  39.21  4453.95  8.31 
C 202 T6 Lytic  0.19  6.27  43.81  1698.79  5.66 
C 203 T10 Mixed  0.20  7.49  47.83  3032.91  8.34 
C 207 L4 Mixed  0.21  9.61  52.51  4649.90  8.97 
C 208 T11 Blastic  0.21  7.69  48.37  3591.92  8.80 
C 212 L5 Mixed  0.27  12.99  42.00  5901.75  14.35 
C 213 L3 Blastic  0.20  9.08  55.45  3899.27  9.11 
D 164 T11 Mixed  0.13  4.91  27.91  2395.72  4.74 
D 168 L3 Mixed  0.15  7.57  50.58  3201.55  6.88 
D 171 L5 Blastic  0.16  7.46  48.42  3884.66  6.20 
D 172 T10 Mixed  0.12  4.43  25.79  1849.35  3.82 
D 175 L1 Lytic  0.14  5.79  33.70  2757.27  4.83 
D 191 L2 Mixed  0.14  6.09  30.84  3753.34  5.49 
E 265 L1 Blastic  0.18  5.80  37.36  3758.41  8.78 
E 266 T12 Blastic  0.19  5.90  43.30  3901.26  9.96 
E 290 T9 Blastic  0.19  5.24  32.96  2809.90  7.38 
F 245 L3 Lytic  0.16  5.94  38.06  3712.16  6.60 
F 246 T10 Mixed  0.13  4.16  32.71  1832.54  4.93 
F 250 T9 Lytic  0.12  3.42  29.04  1633.02  4.59 
G 194 L5 Mixed  0.24  13.78  157.33  4603.28  15.41 
G 195 T5 Lytic  0.23  5.84  83.08  1390.29  5.99 
G 197 L4 Blastic  0.18  12.01  76.70  4748.03  10.16 
H 217 L1 Blastic  0.41  –  128.53  6934.06  21.26 
H 229 L5 Blastic  0.38  –  110.41  7109.02  13.62 
H 233 L4 Blastic  0.33  11.50  90.87  6336.46  10.95 
H 234 T9 Mixed  0.25  5.73  49.97  3426.46  8.20 
H 237 T12 Blastic  0.34  11.56  100.44  6006.08  14.29 
H 238 T8 Blastic  0.21  5.32  45.91  2888.37  9.69 
I 225 T11 Lytic  0.09  1.89  21.00  973.10  3.26 
J 293 L1 Blastic  0.15  4.98  28.59  4413.45  6.60 
J 294 T10 Blastic  0.13  4.64  30.94  2515.80  5.17 
J 302 T6 Mixed  0.13  4.82  36.78  1396.17  3.92 
K 241 L3 Blastic  0.37  10.85  95.82  5576.22  12.22 
K 269 L1 Blastic  0.38  10.83  85.41  5666.50  13.69 
K 270 T12 Blastic  0.39  12.27  105.82  4268.17  13.45 
K 273 L4 Blastic  0.39  –  150.09  4263.83  16.19 
K 274 T11 Blastic  0.39  11.07  85.41  3971.01  11.78  
Appendix B. Supplementary data 
Supplementary data to this article can be found online at https://doi.org/10.1016/j.bone.2020.115598.  
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